Skip to content
OpenCapital
Get started

Viatris VTRS Greater China — Cost of Sales

Similar metrics at other companies

Apple logo
AAPLGreater China — Cost of Sales
$10.63B+20.9%
USANA Health Sciences logo
USNAGreater China — Net Sales
$123.33M+3.9%
QuidelOrtho Corporation logo
QDELChina — Cost of sales, excluding amortization of intangibles
$32M-6.4%
Apple logo
AAPLGreater China — Sales & Marketing
$675M+16.0%
NuSkin Enterprises logo
NUSMainland China — Cost of Goods Sold
$8.01M-10.9%
Marriott International logo
MARGreater China — G&A
$12M0.0%

Other financials

Income statement

See full
Revenue$3.5B+8.1%
Gross profit$1.2B-0.3%
Operating income-$79.7M+97.2%
Net income$176.4M+106%
EPS (diluted)$0.15+106%

Balance sheet

See full
Cash & equivalents$1.8B+139%
Total debt$14.6B+1.0%
Total equity$14.7B-6.3%
Total assets$36.8B-4.3%

Cash flow

See full
Operating cash flow$388.3M-27.5%
CapEx$39.9M-6.3%
Free cash flow$348.4M-29.3%

Valuation

See full
Market cap$18.49B+81.7%
Enterprise value$31.3B+29.5%
P/S1.3×+0.5×

Profitability

See full
Gross margin34.4%-2.5pp
Operating margin1%—
Net margin-2%-1.0pp
FCF margin12.3%-1.0pp

Returns & leverage

See full
Return on equity-2%-0.9pp
Debt / equity1×+0.1×
Current ratio1.6×-0.1×

Where this comes from

Reported directly by Viatris in its filing.

Tagged under the XBRL concept vtrs:CostOfProductAndServiceSoldAdjusted.

The official record: Viatris’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viatris's greater china — cost of sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viatris's greater china — cost of sales?
Viatris (VTRS) reported greater china — cost of sales of $70.9M in Q1 2026.
How has Viatris's greater china — cost of sales changed year-over-year?
Viatris's greater china — cost of sales increased by 16.6% year-over-year, from $60.8M to $70.9M.
What is the long-term trend for Viatris's greater china — cost of sales?
Over 3 years (2022 to 2025), Viatris's greater china — cost of sales has grown at a 8.6% compound annual growth rate (CAGR), from $195.8M to $250.6M.
What does greater china — cost of sales mean?
The direct costs attributable to the production and distribution of pharmaceutical products sold within the Greater China segment. This includes raw materials, manufacturing labor, and logistics expenses required to bring products to market.